Aspirin to Prevent Preeclampsia in Women With Elevated Blood Pressure and Stage 1 Hypertension (ASPPIRE)

Model scores of the 29,894 trials active now.

Model score 18% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (446 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-06-22. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: transplantationto determinegestationgestational agepositive
  Phrases that lowered it: blood pressureaspirinhypertensionasthmawomen
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 12.0% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 137 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 9.6% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Blinding: triple (raises risk) · Design
• Sponsor's past trials: 692 (raises risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Drug's FAERS reports in the prior 12 months: 51245 (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 518445 (lowers risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Role of ASpirin in Placental and Maternal Endothelial Cell Regulation IN Pre-eclampsia NCT03893630 · started 2019 · scored riskier than 10% of active trials completed
• Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida NCT03961360 · started 2019 · scored riskier than 76% of active trials completed
• Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia NCT02059135 · started 2014 · scored riskier than 59% of active trials completed
• Combined Multi-marker Screening and Treatment With Aspirin for Pre-eclampsia Prevention NCT02301780 · started 2015 · scored riskier than 12% of active trials completed
• Detection of False Positives From First-trimester Preeclampsia Screening (StopPRE) at the Second-trimester of Pregnancy NCT03741179 · started 2019 · scored riskier than 15% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.